Creabilis adds three executives to management team
Reflects growing confidence in pipeline and science that underpins it
Alex Leech joins as vice president, head of finance and operations, James Sandy as senior vice president, head of development, and Peter Spargo as senior vice president for chemistry manufacturing and controls (CMC).
Leech was most recently head of operations at Solace Pharmaceuticals. Prior to this, he worked for the Pfizer r&d organisation where he was head of European project management. He has also held a number of operational and engineering management roles at Ford. Sandy was most recently at Pfizer as development team leader of Pfizer’s GI portfolio. Prior to working at Pfizer, he was head of biometrics at Astra UK.
Spargo was most recently at Novexel as senior vice president of CMC. Prior to this he was head of chemical process r&d for Pfizer in Europe.
Eliot Forster, ceo of Creabilis, said: ‘This expansion of our senior management team reflects Creabilis’ growing maturity and the confidence we have in our pipeline, our science and the culture that underpins it.’
You may also like
Regulatory
MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results
The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled
Manufacturing
Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours
The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio
Research & Development
AlzeCure Pharma publishes response letter clarifying Alzstatin’s distinct mechanism in Alzheimer’s treatment
AlzeCure Pharma and leading academic collaborators have published a response in JPET addressing recent commentary on Alzstatin’s γ-secretase modulation data, reaffirming the promise of lead candidate ACD680 in Alzheimer’s therapy